Abstract: A suspension formulation for therapeutic use includes a non-aqueous, single-phase vehicle exhibiting viscous fluid characteristics and a particle formulation comprising an erythropoietin receptor agonist dispersed in the vehicle.
Type:
Grant
Filed:
August 1, 2005
Date of Patent:
August 10, 2010
Assignee:
Alza Corporation
Inventors:
Kui Liu, Michael A. Desjardin, Beth L. Hill, Zengji Li
Abstract: The invention relates to erythropoietin liquid formulations that are stable in storage and to a method for the production thereof. The invention particularly relates to erythropoietin liquid formulations, which contain at least four amino acids selected from the group consisting of leucine, isoleucine, threonine, glutamic acid, aspartic acid and phenylalanine, and in which the addition of preservatives, urea or human serum albumine can be foregone.
Abstract: Methods and compositions are provided for protecting or enhancing an erythropoietin-responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of an erythropoietin receptor activity modulator, such as an erythropoietin or a modified erythropoietin.
Type:
Grant
Filed:
June 26, 2002
Date of Patent:
August 3, 2010
Assignee:
The Kenneth S. Warren Institute, Inc.
Inventors:
Michael Brines, Anthony Cerami, Carla Cerami
Abstract: The invention relates to methods for potentiating, enhancing or restoring glucose responsivity in pancreatic islets or cells. The methods can be used as therapies for diseases caused by, or coincident with, aberrant glucose metabolism, such as Type II Diabetes Mellitus.
Abstract: The use of IL-22 for the treatment of metabolic disorders including hyperlipidemia, obesity, hyperinsulinemia and diabetes. IL-22 may also be used in combination with insulin for diabetes.
Abstract: A method is described for using an E-domain peptide for the induction of apoptosis in a cancer cells. In particular, the invention relates to methods for using a-type E-domain peptide from trout IGF and/or a b-type E-domain peptide from human IGF for the induction of apoptosis in a broad spectrum of cancer cells. The peptide species can be a homologue of the E-domain of IGF-1 or a fusion protein comprising the E-domain of IGF-1. It can be administered to one or more cancer cells alone or in a pharmaceutically acceptable composition.
Abstract: Described are methods for identifying, selecting, and obtaining mammalian cells capable of producing proteinaceous molecules having predetermined post-translational modifications, wherein the post-translational modifications are brought about by the mammalian cell in which the proteinaceous molecule is expressed. Preferably, the predetermined post-translational modifications include glycosylation. Also described are methods for obtaining and producing proteinaceous molecules, using mammalian cells obtainable by a method of the present invention. Preferably, the proteinaceous molecules include erythropoietin (EPO), since EPO's effect depends heavily on its glycosylation pattern. Mammalian cells that have been obtained on the basis of their ability to produce proteins and/or post-translational modifications that are indicative for a predetermined post-translational modification that is desired are also provided.
Type:
Grant
Filed:
August 1, 2007
Date of Patent:
April 13, 2010
Assignee:
Crucell Holland B.V.
Inventors:
Dirk Jan Elbertus Opstelten, Johan Christiaan Kapteyn, Petrus Christianus Johannes Josephus Passier, Ronald Hendrik Peter Brus, Abraham Bout
Abstract: The use of IL-22 for the treatment of metabolic disorders including hyperlipidemia, obesity, hyperinsulinemia and diabetes. IL-22 may also be used in combination with insulin for diabetes.
Abstract: The invention concerns a method for detecting disorders of iron metabolism and in particular the differential diagnosis of disorders of iron metabolism by means of three independent parameters. The differential diagnosis can be used to classify disorders of iron metabolism and to recommend the required treatment and to monitor the progress and response to treatment.
Type:
Grant
Filed:
May 30, 2003
Date of Patent:
February 9, 2010
Assignee:
Roche Diagnostics Corporation
Inventors:
Ralf Roddiger, Paul Lehmann, Lothar Thomas
Abstract: The present invention provides a method for predicting the likely timing of the onset of menopause for a perimenopausal female subject by determining the amount of hLH?cf in a sample from the subject comprising the steps of: (a) contacting a sample from the subject with an antibody which specifically binds to hLH?cf without substantially cross-reacting with hLH, hLH? or hLH?cf, under conditions permitting formation of a complex between the antibody and hLH?cf; (b) measuring the amount of complex formed, so as to thereby determine the amount of hLH?cf in the sample; and (c) comprising the amount of hLH?cf in the subject's sample determined in step (b) with either (i) the amount determined for known postmenopausal female subject or (ii) the amount determined for a sample from a known premenopausal female subject, wherein an amount of hLH?cf in the sample similar to the amount of hLH?cf in the known postmenopausal sample indicates temporal proximity to the onset of menopause, and an amount of hLH?cf in the sampl
Type:
Grant
Filed:
February 10, 2003
Date of Patent:
February 2, 2010
Assignee:
The Trustees of Carolina University in the City of New York
Inventors:
Steven Birken, Yacov Maydelman, Galina I. Kovalevskaya, John F. O'Connor
Abstract: A method of treating, preventing, delaying the onset, and/or reducing the effects of proinflammatory cytokines in conditions including, but not limited to, sepsis, adhesion formation, wounds, organ failure, chronic disease, general inflammatory conditions resulting from infection, scarring resulting from injury and incisions, and combinations thereof.
Type:
Grant
Filed:
September 29, 2004
Date of Patent:
January 12, 2010
Assignees:
The Kenneth S. Warren Institute, Inc., Warren Pharmaceuticals, Inc.
Inventors:
Michael Brines, Anthony Cerami, Thomas Coleman, Osman Yilmaz
Abstract: Formulations and methods to promote biological processes to form or regenerate new hard tissues such as bones, cartilage, and/or dental tissues are disclosed. The formulation comprising two proteins is administered to enhance biological activities of a hard tissue growth and differentiation factor characterized by specific and selective upregulation and/or extension of the retention time of the intracellular enzymes and signaling molecules that play important roles to proliferate, differentiate, maturate, and/or mineralize the hard tissue forming cells.
Type:
Grant
Filed:
July 12, 2006
Date of Patent:
December 29, 2009
Assignee:
Acologix, Inc.
Inventors:
Mirella Lazarov, Catherine Middleton-Hardie, David Rosen
Abstract: The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis.
Type:
Grant
Filed:
November 22, 2000
Date of Patent:
December 15, 2009
Assignee:
Amgen, Inc.
Inventors:
William J. Boyle, David L. Lacey, Frank J. Calzone, Ming-Shi Chang
Abstract: A novel group of gastrokines called Gastric Antrum Mucosal Protein is characterized. A member of the group is designated AMP-18. AMP-18 genomic DNA, cDNA and the AMP-18 protein are sequenced for human, mouse and pig. The AMP-18 protein and active peptides derived from it are cellular growth factors. Surprisingly, peptides capable of inhibiting the effects of the complete protein, are also derived from the AMP-18 protein. Cytoprotection and control of mammalian gastro-intestinal tissue growth and repair (restitution) is facilitated by the use of the proteins, making the proteins candidates for therapies in inflammatory bowel disease, mucositis, and gastric ulcers.
Type:
Grant
Filed:
May 11, 2004
Date of Patent:
December 8, 2009
Assignee:
The University of Chicago
Inventors:
F. Gary Toback, Terence E. Martin, Margaret M. Walsh-Reitz
Abstract: Formulations and methods to promote biological processes to form or regenerate new hard tissues such as bones, cartilage, and/or dental tissues are disclosed. The formulation enhances biological activities of a hard tissue growth and differentiation factor characterized by specific and selective upregulation and/or extension of the retention time of the intracellular enzymes and signaling molecules that play important roles to proliferate, differentiate, maturate, and/or mineralize the hard tissue forming cells.
Type:
Grant
Filed:
July 12, 2006
Date of Patent:
November 24, 2009
Assignee:
Acologix, Inc.
Inventors:
Mirella Lazarov, Catherine Middleton-Hardie, David Rosen
Abstract: A method for treating a cerebrovascular disease with erythropoietin (EPO) and granulocyte-colony stimulating factor (G-CSF) jointly by first identifying a subject in need of the treatment and then administering to the subject an effective combined amount of EPO and G-CSF. Also disclosed is a method for increasing in a subject expression of EPO with G-CSF.
Abstract: The present invention relates to formulations of hCG for sublingual administration to mammals to facilitate weight loss and/or body contouring. Embodiments of the invention disclose administration of hCG formulations in combination with a low calorie diet and dietary supplements and, in some cases, with an exercise regime. Embodiments of this invention also disclose transdermal hCG formulations and hCG formulations for administration through other administration routes.
Abstract: The invention concerns a method for detecting disorders of iron metabolism and in particular the differential diagnosis of disorders of iron metabolism by means of three independent parameters. The differential diagnosis can be used to classify disorders of iron metabolism and to recommend the required treatment and to monitor the progress and response to treatment.
Type:
Grant
Filed:
September 12, 2002
Date of Patent:
October 13, 2009
Assignee:
Roche Diagnostics Corporation
Inventors:
Ralf Roddiger, Paul Lehmann, Lothar Thomas
Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example.
Type:
Grant
Filed:
January 4, 2005
Date of Patent:
September 29, 2009
Assignee:
California Institute of Technology
Inventors:
Hai U. Wang, Zhoufeng Chen, David J. Anderson